A plan by the National Cancer Institute (NCI) to restructure its clinical trials system is under way and is expected to dramatically change the way NCI-funded multicenter trials are proposed, reviewed, and coordinated.
Under the new system, for example, proposals for clinical trials, traditionally the turf of the NCI's Clinical Trial Cooperative Groups, will be drawn from a variety of sources, including clinical and basic scientists from academia and industry, patient advocacy groups, and others. Each proposal will also be judged competitively through a new peer review process involving a disease-specific Concept Evaluation Panel, two thirds of whose members come from outside the NCI.
Stephenson J. Cancer Clinical Trials. JAMA. 1999;282(3):226. doi:10.1001/jama.282.3.226-JHA90005-3-1